JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30

JOHNSON & JOHNSON

2025-Q1 EPS reported $4.54 revenue$21,893,000,000

GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.
Adjusted net earnings $6.71B ($2.77 diluted EPS) vs $6.58B ($2.71), up 1.9% operationally.
Worldwide sales $21.89B, up 2.4% reported, 4.2% operational; US +5.9%, International -1.8%.
Innovative Medicine $13.87B (+2.3% reported, +4.2% op); MedTech $8.02B (+2.5% reported, +4.1% op).
Dividend raised 4.8% to $1.30/quarter, payable June 10, 2025; record May 27, 2025; 63rd annual increase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.